Abstract
Glutamic acid decarboxylase (GAD)-alum (Diamyd ®, Diamyd Medical, Stockholm, Sweden) is an adjuvant-formulated vaccine incorporating recombinant human GAD65, the specific isoform of GAD expressed in human pancreatic β-cells and a major antigen targeted by autoreactive T lymphocytes in Type 1 diabetes mellitus. Intermittent vaccination with this protein is theorized to induce immune tolerance to GAD65, thereby potentially interrupting further β-cell destruction. Hence, clinical trials are ongoing to examine the efficacy and safety of GAD-alum immunotherapy in patients with autoimmune-mediated forms of diabetes, including Type 1 diabetes and latent autoimmune diabetes in adults.
| Original language | English |
|---|---|
| Pages (from-to) | 323-332 |
| Number of pages | 10 |
| Journal | Immunotherapy |
| Volume | 3 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2011 |
Keywords
- C-peptide
- GAD-alum
- LADA
- autoimmune diabetes
- rhGAD65
- β-cell
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
